Astellas' Phase III Front-Line AML Study Of Xospata Fails

Standard Of Care Has Shifted Since Trial's Initiation

 
• By Alaric DeArment
  
Acute myeloid leukemia a 3d-Render
Astellas said its Phase III study of Xospata in front-line AML did not show an overall survival benefit. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D